Targeting VEGFR2, the VEGFA receptor that is essential for endothelial cell functions associated with angiogenesis, enhances the anti-tumor activity of EGFR-TKIs in NSCLC with EGFR-TKI resistance (Li et al., 2017). This evidence concerns the gene EGFR and neoplasm.